SY-12696 / Shouyao Holdings - LARVOL DELTA

SY-12696, a novel and potent MALT1 protease inhibitor, for the treatment of B-cell lymphomas (AACR 2025) - "Based on current studies, SY-12696 has demonstrated significant inhibitory potency on ABC-DLBCL cancer cells in vitro and in vivo, which makes SY-12696 a promising candidate for further development as a monotherapy or in combination with BTKi to treat relapsed/refractory B-cell lymphoma, particularly those resistance to BTKi."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CARD11 • CD79A • MALT1 • MYD88